Darunavir Ethanolate API

Darunavir Ethanolate API is an antiretroviral medication primarily used in the treatment of HIV-1 infection. It is a protease inhibitor (PI), a class of drugs that works by inhibiting HIV protease, an enzyme necessary for the virus's reproduction. In highly active antiretroviral therapy or combination antiretroviral therapy, darunavir is typically used in conjunction with other antiretroviral medications. This combination therapy is designed to reduce viral load, increase CD4+ T-cell counts, and improve overall quality of life for people living with HIV. Darunavir ethanolate is a prodrug, which means that it is metabolized into its active form in the body.

Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.

Darunavir inhibits HIV-1 protease, the enzyme that cleaves the viral Gag and Gag-Pol polyproteins during particle maturation. When this cleavage is blocked, newly produced viral particles remain immature and lack normal infectivity. The compound acts at the maturation stage of the viral life cycle; it does not directly eliminate latent viral reservoirs.

Darunavir was designed with structural features that mimic aspects of the protease substrate's cleavage transition state. Its bis-tetrahydrofuran group forms important interactions with the backbone of the protease active site. These interactions help explain why darunavir can retain activity against some protease variants, although resistance can still develop

Antiviral evaluation should extend beyond assays using wild-type HIV-1. For viruses exposed to earlier protease inhibitors, interpretation requires the resistance genotype, phenotypic susceptibility, treatment history, and the complete antiretroviral regimen.

Protease substitutions associated with reduced darunavir susceptibility include V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, and L89V. Their effects depend on the combination of mutations and the surrounding viral genetic background. Useful research endpoints include inhibitory concentration, fold change relative to wild-type virus, viral replication capacity, and the effects of mutation combinations. API purity alone cannot establish susceptibility in a resistant viral isolate.

In darunavir ethanolate, ethanol is incorporated into the crystal structure. Its solid-state identity can change when the material is exposed to different temperatures, humidity levels, or solvent environments. Published studies have described transitions involving the ethanolate, hydrate, and amorphous forms, including changes associated with desolvation or high humidity. Such transitions may affect processing and dissolution behavior.

A material labeled "Darunavir Ethanolate" should therefore be characterized beyond appearance and chromatographic assay. Relevant tools include powder X-ray diffraction (XRPD) for crystal form, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) for thermal behavior, validated methods for ethanol and water content, and dynamic vapor sorption (DVS) for humidity response.

Darunavir is a structurally complex molecule with defined stereochemical requirements. Process research should examine the selective construction of its key chiral features, coupling efficiency, and whether the final crystallization consistently produces the intended ethanolate form.

An impurity-control strategy should consider:

- Process-related impurities: unreacted intermediates, reaction by-products, and stereoisomeric impurities;

- Degradation products: compounds formed under relevant heat, humidity, light, oxidative, or solution conditions;

- Solvents and inorganic impurities: residual processing solvents, catalysts, and relevant elemental impurities.